Company / EPS (Diluted)
Veracyte, Inc. EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$1.02
FY2025
5-year range
-$1.11 / -$0.27
FY2021-FY2025
Trend
-100.0%
vs FY2024
Sector context
#122 of 159
Health Care
What the data says
Veracyte, Inc.'s eps (diluted) of $-1.02 is lower than 77% of companies in the Health Care sector (FY2025). EPS (Diluted) has fluctuated over the past 10 years, ranging from $-1.36 in FY2016 to $-0.27 in FY2021.
Based on SEC 10-K filings.
-1.02 in FY2025.
Improved from $-1.11 to $-1.02 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
Bottom 23% in Health CareTop 77% of 159This company -$1.02 Sector average $1.64
▼
-162.3% below sector average
Key checks
Key Insights
- In FY2025, eps (diluted) decreased 100.0% year-over-year.
- Ranks #122 out of 159 companies in the Health Care sector.
- Peak eps (diluted) was recorded in FY2021.
- Lowest eps (diluted) in the period was in FY2016.
Company context
Key Data Points
- Altman Z-Score 6.19 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$1.02 | -100.0% |
| FY2024 | -$0.51 | +54.1% |
| FY2023 | -$1.11 | -68.2% |
| FY2022 | -$0.66 | -144.4% |
| FY2021 | -$0.27 | +56.5% |
| FY2020 | -$0.62 | +31.9% |
| FY2019 | -$0.91 | +16.5% |
| FY2018 | -$1.09 | +16.2% |
| FY2017 | -$1.30 | +4.4% |
| FY2016 | -$1.36 | +77.9% |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026